Cancer risk in people with epilepsy: The role of antiepileptic drugs

Brain

Volumn 128, Issue 1, 2005, Pages 7-17

  Singh, Gagandeep ^a   Driever, Pablo Hernáiz ^b   Sander, Josemir W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antiepileptic drugs; Cancer; Carcinogenicity; Co morbidity; Epilepsy

Indexed keywords

9 AMINOCAMPTOTHECIN; ANTICONVULSIVE AGENT; BUSULFAN; CARBAMAZEPINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; GABAPENTIN; HISTONE DEACETYLASE; IFOSFAMIDE; IRINOTECAN; LAMOTRIGINE; LOMUSTINE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; PENTOBARBITAL; PHENOBARBITAL; PHENYTOIN; PREGABALIN; SECOBARBITAL; TAMOXIFEN; TEMSIROLIMUS; TENIPOSIDE; TOPOTECAN; VALPROIC ACID; VINCRISTINE;

ADRENAL TUMOR; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BONE MARROW SUPPRESSION; BRAIN TUMOR; CANCER CELL CULTURE; CANCER INCIDENCE; CANCER RISK; CARCINOGENICITY; CHILD; CHILDHOOD CANCER; DRUG SAFETY; ENZYME INHIBITION; EPENDYMOBLASTOMA; EPILEPSY; FEMALE; FETAL HYDANTOIN SYNDROME; FEVER; GASTROINTESTINAL TOXICITY; GENOTOXICITY; HEMATOLOGIC MALIGNANCY; HEPATOSPLENOMEGALY; HODGKIN DISEASE; HUMAN; HYPERPLASIA; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER TUMOR; LUNG CANCER; LYMPHADENOPATHY; LYMPHOBLASTOMA; LYMPHOID CELL; LYMPHOMA; MALE; MOUSE; MULTIPLE MYELOMA; MYELOMA; NEURAL TUBE DEFECT; NEUROBLASTOMA; NEUROECTODERM TUMOR; NONHUMAN; PERIPHERAL NEUROPATHY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PSEUDOLYMPHOMA; RASH; RAT; REVIEW; SKIN CANCER; SOLID TUMOR; TERATOGENICITY; URINARY TRACT CANCER;

EID: 11344284145     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awh363     Document Type: Review

References (137)

1. Abbondanzo SL, Irey NS, Frizzera G. Dilantin-associated lymphadenopathy. Spectrum of histopathological patterns. Am J Surg Pathol 1995; 119: 675-85.
2. Alberts DS, van Daalen Wetters T. The effect of phenobarbital on cyclophosphamide antitumor activity. Cancer Res 1976; 36: 2785-9.
3. Alberts DS, Peng YM, Chen HS, et al. Effect of phenobarbital on plasma levels of cyclophosphamide and its metabolites in the mouse. Br J Cancer 1978; 38: 316-24.
4. Al-Shammri SA, Guberman A, Hsu E. Neuroblastoma and foetal exposure to phenytoin in a child without dysmorphic features. Can J Neurol Sci 1992; 19: 243-5.
5. Allen RW, Ogden B, Bentley FL, Jung AL. Foetal hydantoin syndrome, neuroblastoma and hemorrhagic disease in a neonate. J Am Med Assoc 1980; 244: 1464-5.
6. Anthony JJ. Malignant lymphoma associated with hydantoin drugs. Arch Neurol 1970; 22: 450-4.
7. Annegers JF, Kurland LT, Hauser WA. Brain tumors in children exposed to barbiturates. J Natl Cancer Inst 1979; 63: 3.
8. Aymard JP, Lederlin P, Witz F, Colomb JN, Faure G, Guerci O, Herbeuval R. Multiple myeloma after phenytoin therapy. Scand J Haematol 1981; 26: 330-2.
9. Baker AF, Dorr RT. Drug interactions with the taxanes: clinical implications. Cancer Treat Rev 2001; 27: 221-33.
10. Baker DK, Relling MV, Pui CH, Christensen ML, Evans WE, Rodman JH. Increased teniposide clearance with concomitant anticonvulsant therapy. J Clin Oncol 1992; 10: 311-5.
11. Bardana EJ, Gabourel JD, Davies GH, Craig S. Effect of phenytoin on man's immunity. Evaluation of changes in serum immunoglobulins, complement and antinuclear antibody. Am J Med 1983; 74: 289-96.
12. Becker FF. Tumor phenotype and susceptibility to progression as an expression of subpopulations of initiated murine cells. Cancer Res 1985; 45: 768-73.
13. Bell GS, Sander JW. The epidemiology of epilepsy: the size of the problem. Seizure 2001; 10: 306-14.
14. Bell GS, Gaitatzis A, Johnson AL, Sander JW. Predictive value of death certification in the case ascertainment of epilepsy. J Neurol Neurosurg Psychiatry 2004; 75: 1756-8.
15. Benedetti MS. Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol 2000; 14: 301-19.
16. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs. Epilepsy Research 2004; 61: 1-48.
17. Blaheta RA, Cinatl J Jr. Anti-tumour mechanisms of valproate: a novel role for an old drug. Med Res Rev 2002; 22: 492-511.
18. Blaheta R, Hernáiz Driever P, Michaelis M, Cinatl J. The evolving anticancer drug Valproic acid: Insights into the mechanism and clinical studies-an update. Curr Med Chem. In press 2004.
19. Brodtkorb E, Nakken KO, Steinlein OK. No evidence for a seriously increased malignancy risk in LGl1-caused epilepsy. Epilepsy Res 2003; 56: 205-8.
20. Chhabra RS, Bucher JR, Haseman JK, Elwell MR, Kurtz PJ, Carlton BD. Comparative carcinogenicity of 5,5-diphenylhydantoin with or without perinatal exposure in rats and mice. Fundam Appl Toxicol 1993; 21: 174-86.
21. Chang TK, Chen G, Waxman DJ. Modulation of thiotepa antitumor activity in vivo by alteration of liver cytochrome P450-catalyzed drug metabolism. J Pharmacol Exp Ther 1995; 274: 270-5.
22. Chang SM, Kuhn JG, Rizzo J, Robins HI, Schold SC, Spence AM, Berger MS, Mehta MP, Bozik ME, Pollack I, Gilbert M, Fulton D, Rankin C, Malec M. Prados MD. Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol 1998; 16: 2188-94.
23. Chang SM, Kuhn J, Wen P, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, Cloughesy T, De Angelis L, Razier J, Hess K, Dancey J, Prados MD. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs 2004; 22: 427-35.
24. Chen G, Manji MK, Hawver DB, Wright CB, Potter WZ. Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro. J Neurochem 1994; 63: 2361-4.
25. Chen G, Masana MI, Manji HK. Lithium regulates PKC-mediated intracellular cross-talk and gene expression in the CNS in vivo. Bipolar Disord 2000; 2: 217-36.
26. Choi TS, Doh KS, Kim SH, Jang MS, Suh KS, Kim ST. Clinicopathological and genotypic aspects of anticonvulsant-induced pseudolymphoma syndrome. Br J Dermatol 2003; 148: 730-6.
27. Ciba Geigy. Product monograph-Tegretol; 1987.
28. Cinatl J Jr, Cinatl J, Driever PH, Kotchetkov R, Pouckova P, Komhuber B, Schwabe D. Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anticancer Drugs 1997; 8: 958-63.
29. Cinatl J Jr, Kotchetkov R, Blaheta R, et al. Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon. Int J Oncol 2002; 20: 97-106.
30. Clemmesen J, Hjalgrim-Jensen S. Is phenobarbital carcinogenic? A follow-up of 8078 epileptics. Ecotoxicol Environ Saf 1978; 1: 457-70.
31. Clemmesen J, Hjalgrim-Jensen S. Does phenobarbital cause brain tumors? A follow-up through 35 years. Ecotoxicol Environ Saf 1981; 5: 255-60.
32. Cooke LE, Hardin TC, Hendrickson DJ. Phenytoin-induced pseudolymphoma with mycosis fungoides like manifestations. Clin Pharm 1998; 7: 153-7.
33. Creange A, Zeller J, Rostaing-Rigattieri S, Brugieres P, Degos JD, Revuz J, Wolkenstein P. Neurological complications of neurofibromatosis type I in adulthood. Brain 1999; 122: 473-81.
34. Crews KR, Stewart CF, Jones-Wallace D, Thompson SJ, Houghton PJ, Heideman RL, Fouladi M, Bowers DC, Chintagumpala MM, Gajjar A. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clin Cancer Res 2002; 8: 2202-9.
35. Cusack BJ, Tesnohlidek DA, Loseke VL, Vestal RE, Brenner DE, Olson RD. Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit. Cancer Chemother Pharmacol 1988; 22: 294-8.
36. Diwan BA, Rice JM, Nims RW, Lubet RA, Hu H, Ward JM. P-450 enzyme induction by 5-ethyl-5-phenylhydantoin and 5,5-diethylhydantoin, analogues of barbiturate tumor promoters phenobarbital and barbital, and promotion of liver and thyroid carcinogenesis initiated by N-nitrosodiethylamine in rats. Cancer Res 1988; 48: 2492-7.
37. Diwan BA, Henneman JR, Rice JM. Further evidence for promoter-dependent development of hepatoblastoma in the mouse. Cancer Lett 1995; 89: 29-35.
38. Diwan BA, Henneman JR, Nims RW. Enhancement of N-nitrosodiethyl-amine- initiated hepatocarcinogenesis by phenytoin in male F344/Ner rats at a dose causing maximal induction of CYP2B. Int J Toxicol 2001; 20: 81-7.
39. Driever HP, Knüpfer M, Cinatl J, Wolff J. Valproic acid for the treatment of pediatric malignant glioma. Klin Pädiat 1999; 211: 323-8.
40. Driver HE, McLean AEM. Dose response relationship for phenobarbitone promotion of liver tumors initiated by single dose dimethylnitrosamine. Br J Exp Pathol 1986; 67: 131-9.
41. Ehrenbard LT, Chaganti K. Cancer in foetal hydantoin syndrome. Lancet 1981; 8237: 97.
42. European Medicine Evaluation Agency. Pregabalin (Lyrica). www. emea.eu.int/humandocs/PDFs/EPAR/lyrica/084504en6.pdf. Accessed 16 November 2004.
43. Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M. The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 2004; 45: 737-44.
44. Fatihi el M, Khanfri N, Niang A, et al. Renal manifestations of tuberous sclerosis complex. Ann Med Interne 2003; 154: 255-8.
45. Fertig E, Lincoln A, Martinuzzi A, et al. Novel LGI1 mutation in a family with autosomal dominant partial epilepsy with auditory features. Neurology 2003; 60: 1687-90.
46. Fetell MR, Grossman SA, Fisher JD, et al. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. J Clin Oncol 1997; 15: 3121-8.
47. Fleischmann WR Jr, Ramarathinam N, Fields EE. Effects of phenytoin on the production of interferons: differential effects on type I and type 11 interferons. J Biol Regul Homeost Agents 1990; 4: 107-16.
48. Friedman G. Multiple myeloma: relation to propoxyphene and other drugs, radiation and occupation. Int J Epidemiol 1986; 15: 424-6.
49. Friedman GD, Ury HK. Initial screening for carcinogenicity of commonly used drugs. J Natl Cancer Inst 1980; 65: 723-33.
50. Friedman GD, Ury HK. Screening for possible drug carcinogenicity. Second report of findings. J Natl Cancer Inst 1983; 71: 1165-75.
51. Gaitatzis A, Caroll K, Majed A, Sander JW. The epidemiology of comorbidity of epilepsy in the general population. Epilepsia 2004; 45: 1518-25.
52. Gams RA, Neal JA, Conrad FG. Hydantoin induced pseudo-pseudolymphoma. Ann Intern Med 1968; 69: 557-68.
53. Garcia Suarez J, Dominguez-Franjo P, Del Campo JF. EBV-positive non-Hodgkin's lymphoma developing after phenytoin treatment. Br J Haematol 1996; 95: 376-9.
54. Gold EB, Gordis L, Tonascia JA, et al. Increased risk of brain tumors in children exposed to barbiturates. J Natl Cancer Inst 1978; 61: 1031-4.
55. Goldbaher MK, Selby JV, Hiatt RA. Exposure to barbiturates in utero and during childhood and risk of intracranial tumors. Cancer Res 1990; 50: 4600-3.
56. Gottlicher M. Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. Ann Hematol 2004; 83: S91-S92.
57. Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001; 20: 6969-78.
58. Grossman SA, Hochberg F, Fisher J, et al. Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy. Cancer Chemother Pharmacol 1998; 42: 118-26.
59. Gu W, Brobtkorb E, Steinlien OK. LG11 is mutated in familial temporal lobe epilepsy characterized by aphasic seizures. Ann Neurol 2002; 52: 364-7.
60. Gurney JG, Mueller BA, Preston-Martin S, et al. A study of pediatric brain tumors and their association with epilepsy and anticonvulsant use. Neuroepidemiol 1997; 16: 248-55.
61. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med 2002; 347: 1593-603.
62. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
63. Hassan M, Oberg G, Bjorkholm M, et al. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol 1993; 33: 181-6.
64. Horwitz RI, Feinstein AR. Exclusion bias and the false relationship of reserpine and breast cancer. Arch Intern Med 1985; 145: 1873-5.
65. Hu LJ, Lu XF, Lu BQ, et al. The effect of valproic acid on SCE and chromosomal aberrations in epileptic children. Mut Res 1990; 243: 63-6.
66. Hyman GA, Sommers SC. The development of Hodgkin's disease and lymphoma during anticonvulsant therapy. Blood 1966; 28: 416-27.
67. International Agency for Research on Cancer. Overall evaluations of carcinogenicity. An updating of IARC monographs, volumes 1-42. In: IARC monographs on evaluation of carcinogenic risk to humans (Suppl 7). Lyons, France: IARC; 1987.
68. International Agency for Research on Cancer. http://193.51.164.11/ monoeval/preamble.html. Accessed 01 September 2004.
69. Jeng YM, Tien MF. Su IJ. Phenytoin-induced pseudolymphoma; revaluation using modern biology techniques. Epilepsia 1996; 37: 104-7.
70. Jiminez JF, Seibert RW, Char F, et al. Melanotic neuroectodermal tumor of infancy and foetal hydantoin syndrome. Am J Pediatr Hematol Oncol 1981; 3: 9-15.
71. Kaul A, Goyle S. Genotoxicity of anticonvulsant drug phenytoin (PHT): a follow up study of PHT-untreated epileptic patients. I. Sister chromatid exchange (SCE) analysis. Teratog Carcinog Mutagen 1999; 19: 61-72.
72. Kaul A, Kaller NR, Goyle S II. An altered proliferation response due to the anticonvulsant phenytoin in epileptic patients. Taratog Carcinog Mutagen 2001; 21: 151-64.
73. Knupfer MM, Hernaiz-Driever P, Poppenborg H, et al. Valproic acid inhibits proliferation and changes expression of CD44 and CD56 of malignant glioma cells in vitro. Anticancer Res 1998; 18: 3585-9.
74. Kobau R, Dilorio CA, Price PH, et al. Prevalence of epilepsy and health status of adults with epilepsy in Georgia and Tennessee Behavioral Risk Factor Surveillance System. 2002. Epilepsy Behav 2004; 5: 358-66.
75. Koren G, Demitrakoudis D, Weksberg R, et al. Neuroblastoma after prenatal exposure to phenytoin; cause or effect. Teratology 1989; 40: 157-62.
76. Kruger G. Effect of Dilantin in mice. I. Changes in lymphoreticular tissue after acute exposure. Virchows Arch A Pathol Anat 1970; 349: 297-311.
77. Kruger GRF, Harris D. Is phenytoin carcinogenic? Lancet 1972; 1: 323.
78. Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004; 104: 1266-9.
79. Kuhn JG. Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report. Oncology (Huntingt) 2002; 16(8 Suppl 7): 33-40.
80. Lamminpaa A, Pukkala E, Teppo L, Neuvonen PJ. Cancer incidence among patients using AEDs: a long-term follow-up of 28,000 patients. Eur J Clin Pharmacol 2002; 58: 137-41.
81. Levin VA, Stearns J, Byrd A, et al. The effect of phenobarbital pretreatment on the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl-1-nitrosourea (PCNU), and on the plasma pharmacokinetics and biotransformation of BCNU. J Pharmacol Exp Ther 1979; 208: 1-6.
82. Levo Y, Markowitz O, Trainin N. Hydantoin immunosuppression and carcinogenesis. Clin Exp Immunol 1975; 19: 521-7.
83. Li FP, Willard DR, Goodman R, et al. Malignant lymphoma after diphenylhydantoin (dilantin) therapy. Cancer 1975; 36: 1359-62.
84. Linet MS, Harlow SD, McLaughlin JK. A case control study of multiple myeloma in whites: chronic antigen stimulation, occupation and drug use. Cancer Res 1987; 47: 2978-81.
85. Lipson A, Bale P. Ependymoblastoma associated with prenatal exposure to diphenylhydantoin and methylphenobarbitone. Cancer 1985; 55: 1859-62.
86. Lu H, Wang JJ, Chan KK, Young D. Effects of phenobarbital on stereoselective metabolism of ifosfamide in rats. Drug Metab Dispos 1998; 26: 476-82.
87. Maeda T, Sano N, Togei K, Shibata M, Izumi K, Otsuka H. Lack of carcinogenicity of phenytoin in (C57BL/6 × C3H) F1 mice. J Toxicol Environ Health 1988; 24: 111-9.
88. Mai L, Jope RS, Li X. BDNF-mediated signal transduction is mediated by GSK3 beta and mood stabilizing agents. J Neurochem 2002; 82: 75-83.
89. Mathijssen RH, Sparreboom A, Dumez H, van Oosterom AT, de Bruijn EA. Altered irinotecan metabolism in a patient receiving phenytoin. Anticancer Drugs 2002; 13: 139-40.
90. McGee JH, Butler WH, Erikson DJ. Oncogenic studies with felbamate (2-phenyl 1,3-propanediol dicarbamate). Toxicol Sci 1998; 45: 146-51.
91. Matzner Y, Polliack Y. Lymphoproliferative disorders in four patients receiving chronic diphenylhydantoin therapy: etiological correlation or chance association. Isr J Med Sci 1978; 14: 865-9.
92. Meinardi H, Scott RA, Reis R, Sander JW. The treatment gap in epilepsy: the current situation and ways forward. Epilepsia 2001; 42: 136-49.
93. Michaelis M, Michaelis UR, Fleming I, Suhan T, Cinatl J, Blaheta RA, Hoffmann K, Kotchetkov R, Busse R, Nau H, Cinatl J. Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 2004; 65: 520-7.
94. Moorthy B, Sriram P, Randerath E, Randerath K. Effects of cytochrome P450 inducers on tamoxifen genotoxicity in female mice in vivo. Biochem Pharmacol 1997; 53: 663-9.
95. Murry DJ, Cherrick I, Salama V, Berg S, Bernstein M, Kuttesch N, Blaney SM. Influence of phenytoin on the disposition of irinotecan: a case report. J Pediatr Hematol Oncol 2002; 24: 130-3.
96. Oslen CM, Meussen-Elholm ET, Roste LS, Tauboll E. Antiepileptic drugs inhibit cell growth in human breast cancer cell line MCF7. Mol Cell Endocrinol 2004; 213: 173-9.
97. Olsen JH, Boice JD Jr, Jensen JP, Fraumeni JF Jr. Cancer among epileptic patients exposed to anticonvulsant drugs. J Natl Cancer Inst 1989; 81: 1753-4.
98. Olsen JH, Boice JD, Fraumeni JF Jr. Cancer in children of epileptic mothers and the possible relation to maternal anticonvulsant therapy. Br J Cancer 1990; 62: 996-9.
99. Olsen JH, Wallin H, Bioce JD Jr, Rask K, Schulgen G, Fraumeni JF. Phenobarbital, drug metabolism, and human cancer. Cancer Epidemiol Biomarkers Prev 1993; 2: 449-52.
100. Olsen JH, Schulgen G, Boice JD, Whysner J, Travis LB, Williams GM, et al. Antiepileptic treatment and risk for hepatobiliary cancer and malignant lymphoma. Cancer Res 1995; 55: 294-7.
101. Pendergrass TW. Foetal hydantoin syndrome and neuroblastoma. Lancet 1976; 2: 150.
102. Peraino C, Fry RJM, Staffeldt E. Reduction and enhancement by phenobarbitone of hepatocarcinogenesis induced in the rat by 2-acetylaminoflourene. Cancer Res 1971; 31: 1506-12.
103. Pfizer. Lyrica: Summary of Product Characteristics. Code LYR327; 2004.
104. Ramilo J, Harris NJ. Neuroblastoma in a child with hydantoin and fetal alcohol syndrome. The radiological features. Br J Radiol 1979; 52: 993-5.
105. Ravindranath Y. Down syndrome and acute myeloid leukemia: the paradox of increased risk for leukemia and heightened sensitivity to chemotherapy. J Clin Oncol 2003; 21: 3385-7.
106. Regan CM. Therapeutic levels of sodium valproate inhibit mitotic indices in cells of neural origin. Brain Res 1985; 347: 394-8.
107. Relling MV, Pui CH, Sandlund JT, Rivera GK, Hancock ML, Boyett JM, Schuetz EG, Evans WE. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 2000; 356: 285-90.
108. Rijlaarsden U, Scheffer E, Meijer CJ, Kruyswijk MR, Willemze R. Mycosis fungoides-like lesions associated with phenytoin and carbamazepine therapy. J Am Acad Dermatol 1991; 24: 216-20.
109. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs for treatment of nonepileptic conditions. Nat Med 2004; 10: 685-92.
110. Salztein SL, Ackerman LV. Lymphadenopathy-induced by anticonvulsant drugs and mimicking clinically and pathologically malignant lymphoma. Cancer 1959; 12: 164-82.
111. Sander JW. The epidemiology of epilepsies revisited. Curr Opin Neurol 2003; 16: 165-70.
112. Sander JW. The use of antiepileptic drugs-principles and practice. Epilepsia 2004; (45 Suppl 6): 28-34.
113. Satge D, Sasco AJ, Little J. Antenatal therapeutic drug exposure and foetal/neonatal tumors: review of 89 cases. Pediatr Perinat Epidemiol 1998; 12: 84-117.
114. Schaumann BA, Winge VB, Penderson M. Genotoxicity evaluation in patients on phenobarbital monotherapy by sister chromatid exchange. J Toxicol Environ Health 1989a; 28: 277-84.
115. Schaumann BA, Winge VB, Garry VF. Sister chromatid exchanges in adult epilepsy patients on valproate monotherapy. Epilepsy Res 1989b; 3: 182-4.
116. Schaumann BA, Winge VB, Penderson M, Kuskowski MA. Comparative effects of phenytoin and/or Phenobarbital treatment on sister chromatid exchange. Epilepsia 1990; 31: 453-7.
117. Selby JV, Friedman GD, Fireman BH. Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up. Cancer Res 1989; 49: 5736-47.
118. Seeler RA, Israel JN, Royal JE, Kaye CI, Rao S, Abulaban M. Ganglioneuroblastoma and foetal hydantoin-alcohol syndrome. Pediatrics 1979; 63: 524-7.
119. Sherman S, Roizen N. Foetal hydantoin syndrome and neuroblastoma. Lancet 1976; 2: 517.
120. Shirts SB, Annegers JF, Hauser WA, Kurland LT. Cancer incidence in a cohort of patients with seizure disorder. J Natl Cancer Inst 1986; 77: 83-6.
121. Sigler RE, Gough AW, de la Iglesia FA. Pancreatic acinar cell neoplasia in male Wistar rats following 2 years of gabapentin exposure. Toxicology 1995; 98: 73-82.
122. Sturgill MG, August DA, Brenner DE. Hepatic enzyme induction with phenobarbital and doxorubicin metabolism and myelotoxicity in the rabbit. Cancer Invest 2000; 18: 197-205.
123. Sugie S, Mori M, Takahashi M. Effect of in vivo exposure to liver tumor promoters Phenobarbital or DDT on the gap junctions of rat hepatocytes: a quantitative freeze-fracture analysis. Carcinogenesis 1987; 8: 45-51.
124. Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, Miyakawa I, Koeffler HP. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 2004; 10: 1141-9.
125. Taneja N, Jain S, Maheshwari MC, Tandon JK, Kucheria K. Induction of sister chromatid exchanges in phenytoin treated and untreated patients with epilepsy. Indian J Med Res 1992; 96: 302-5.
126. Tang R, Faussat AM, Majdak P, Perrot JY, Chaoui D, Legrand O, Marie JP, Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia 2004; 18: 1246-51.
127. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2003; 2: 404-9.
128. Villikka K, Kivisto KT, Maenpaa H, Joensuu H, Neuvonen PJ. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther 1999; 66: 589-93.
129. Warner KA, Fernstrom MJ, Ruch RJ. Inhibition of mouse hepatocyte gap junctional intercellular communication by Phenobarbital correlates with strain-specific carcinogenesis. Toxicol Sci 2003; 71: 190-7.
130. Watkins JR, Gough AW, McGuire EJ, Goldenthal E, de la Lglesia FA. Calcium valproate-induced uterine adenocarcinomas in Wistar rats. Toxicology 1992; 71: 35-47.
131. Wells PG, Kim PM, Laposa RR, et al. Oxidative damage in chemical teratogenesis Mutation Res 1997; 396: 65-78.
132. White SJ, McLean AEM, Howland C. Anticonvulsant drugs and cancer. A cohort study in patients with severe epilepsy. Lancet 1979; 2: 458-60.
133. Whysner I, Ross PM, Williams GM. Phenobarbitone mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation and tumour promotion. Pharmacol Ther 1996; 71: 153-91.
134. Yamagi S, Sakamoto M, Ninomiya Y, Kamiya T. Decrease in L-type pyruvate kinase activity in rat liver by some promoters of hepatocarcinogenesis. J Natl Cancer Inst 1984; 73: 887-94.
135. Yao CP, Mather GG, Stephens JR, Levy RH. Cytotoxicity induced by combination of valproic acid and tumour necrosis factor-alpha: implication for valproic acid-associated hepatotoxicity syndrome, Biochem Pharmacol 1999; 58: 455-9.
136. Zamboni WC, Gajjar AJ, Heideman RL, Beijnen JH, Rosing H, Houghton PJ, Stewart CF. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res 1998; 4: 783-9.
137. Zipursky A, Doyle J. Leukemia in newborn infants with Down syndrome. Leuk Res 1993; 17: 195.